Novel drug to shake up big market

Posted 10 August 2022 AM

An international team of researchers hope to test an investigational type 2 diabetes drug called PATAS in clinical trials "as soon as possible" after showing it targets the underlying cause of the condition.

PATAS, is a potential first-in-class peptide biologic, discovered by Inserm researcher Vincent Marion in collaboration with Monash University, the University of Birmingham, and former senior endocrinologist at the FDA, Alexander Fleming.

To see the whole article, please login